Charterhouse Capital Partners has started talks about a GP-led restructuring on its 2009-vintage buyout fund Charterhouse Capital Partners IX, according to a report by Secondaries Investor.
Backers close a $18.6m round started in 2015 with an initial $10.6m capital injection
GP invests via its Nordic Capital Fund IX, which held a final close on €4.3bn in May 2018
Abalos Therapeutics is a biotechnology company focused on developing immuno-oncology therapeutics
Existing management team will lead the company's future growth and development